The urothelial transcriptomic response to interferon gamma predicts T1 recurrence-free and basal/squamous muscle-invasive bladder cancer survival and better targeted strategies for immune checkpoint blocking
View ORCID ProfileSimon C. Baker, Andrew S. Mason, Raphael G. Slip, Pontus Eriksson, View ORCID ProfileGottfrid Sjödahl, Ludwik K Trejdosiewicz, Jennifer Southgate
doi: https://doi.org/10.1101/2022.02.04.22270000
Simon C. Baker
1Jack Birch Unit of Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York YO10 5DD, UK
Andrew S. Mason
1Jack Birch Unit of Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York YO10 5DD, UK
Raphael G. Slip
1Jack Birch Unit of Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York YO10 5DD, UK
Pontus Eriksson
2Lund University Cancer Centre, Lunds Universitet, Box 117, 221 00 Lund, Sweden
Gottfrid Sjödahl
2Lund University Cancer Centre, Lunds Universitet, Box 117, 221 00 Lund, Sweden
Ludwik K Trejdosiewicz
1Jack Birch Unit of Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York YO10 5DD, UK
Jennifer Southgate
1Jack Birch Unit of Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York YO10 5DD, UK
Data Availability
All data produced are available online at GSE174244.
Posted February 06, 2022.
The urothelial transcriptomic response to interferon gamma predicts T1 recurrence-free and basal/squamous muscle-invasive bladder cancer survival and better targeted strategies for immune checkpoint blocking
Simon C. Baker, Andrew S. Mason, Raphael G. Slip, Pontus Eriksson, Gottfrid Sjödahl, Ludwik K Trejdosiewicz, Jennifer Southgate
medRxiv 2022.02.04.22270000; doi: https://doi.org/10.1101/2022.02.04.22270000
The urothelial transcriptomic response to interferon gamma predicts T1 recurrence-free and basal/squamous muscle-invasive bladder cancer survival and better targeted strategies for immune checkpoint blocking
Simon C. Baker, Andrew S. Mason, Raphael G. Slip, Pontus Eriksson, Gottfrid Sjödahl, Ludwik K Trejdosiewicz, Jennifer Southgate
medRxiv 2022.02.04.22270000; doi: https://doi.org/10.1101/2022.02.04.22270000
Subject Area
Subject Areas
- Addiction Medicine (399)
- Allergy and Immunology (710)
- Anesthesia (201)
- Cardiovascular Medicine (2946)
- Dermatology (249)
- Emergency Medicine (440)
- Epidemiology (12752)
- Forensic Medicine (12)
- Gastroenterology (828)
- Genetic and Genomic Medicine (4587)
- Geriatric Medicine (419)
- Health Economics (729)
- Health Informatics (2918)
- Health Policy (1069)
- Hematology (389)
- HIV/AIDS (924)
- Medical Education (426)
- Medical Ethics (115)
- Nephrology (469)
- Neurology (4361)
- Nursing (236)
- Nutrition (639)
- Oncology (2271)
- Ophthalmology (647)
- Orthopedics (258)
- Otolaryngology (325)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (501)
- Pediatrics (1197)
- Primary Care Research (496)
- Public and Global Health (6944)
- Radiology and Imaging (1529)
- Respiratory Medicine (915)
- Rheumatology (438)
- Sports Medicine (385)
- Surgery (489)
- Toxicology (60)
- Transplantation (212)
- Urology (181)